# Next-generation immunotherapy biologics for glioblastoma

## TL;DR

Glioblastoma is hard to treat with immunotherapy, but new biologics are being developed to overcome resistance and improve outcomes.

## Contribution

The paper reviews next-generation immunotherapy biologics and strategies to overcome glioblastoma resistance.

## Key findings

- Anti-PD-1 monotherapy has not improved survival in glioblastoma due to immunosuppressive tumor microenvironment.
- New immunotherapy approaches include cytokine proteins, adoptive cell therapies, and oncolytic viruses.
- Tumor subtyping and immune profiling are essential for effective combination therapies in glioblastoma.

## Abstract

Glioblastoma (GBM) remains largely resistant to immunotherapy despite the success of immune checkpoint inhibitors in other solid tumors. Phase III trials have not demonstrated survival benefit for anti-PD-1 monotherapy, likely reflecting the GBM tumor microenvironment’s profound myeloid-driven immunosuppression, low neoantigen burden, intratumoral heterogeneity, and adaptive resistance. These challenges have driven the development of next-generation immunotherapy biologics designed to reprogram the tumor microenvironment and overcome the innate and adaptive resistance of GBM. This review synthesizes advances in immunotherapy biologics including immune checkpoint combinations, cytokine and immunomodulatory proteins, adoptive cell therapies, vaccines, and oncolytic viruses, highlighting key preclinical insights and emerging clinical trial results. We conclude that improved tumor subtyping and immune profiling will be crucial to guide combination strategies that may achieve durable clinical benefit in GBM.